Welcome to our dedicated page for EIGER BIOPHARMACEUTICALS news (Ticker: EIGRQ), a resource for investors and traders seeking the latest updates and insights on EIGER BIOPHARMACEUTICALS stock.
Eiger Biopharmaceuticals (EIGRQ) is a commercial-stage biopharmaceutical company specializing in innovative therapies for rare metabolic diseases. Their leading product, avexitide, a GLP-1 antagonist, targets post-bariatric hypoglycemia and congenital hyperinsulinism. Eiger recently closed the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, marking a significant acquisition in the field. Zokinvy is the first FDA-approved treatment for progeria, a genetic premature aging disease, with approvals in the US, EU, GB, and Japan. Eiger's collaboration with AnGes for Zokinvy distribution in Japan and its ongoing commitment to rare disease patients highlight the company's dedication to advancing healthcare solutions.
Sentynl Therapeutics, a Zydus Group company, has acquired global rights to Zokinvy® (Lonafarnib) from Eiger BioPharmaceuticals, a treatment for Hutchinson-Gilford Progeria Syndrome. Zokinvy is approved in the U.S., European Union, Great Britain, and Japan for rare genetic diseases. The acquisition aims to broaden the portfolio of medicines for rare diseases, enhancing patient care and well-being.
FAQ
What is the current stock price of EIGER BIOPHARMACEUTICALS (EIGRQ)?
What is the market cap of EIGER BIOPHARMACEUTICALS (EIGRQ)?
What is Eiger Biopharmaceuticals focused on?
What is avexitide, and what conditions does it target?
What is Zokinvy®, and why is it significant?
In which regions has Zokinvy® received approvals?
What recent acquisition has Eiger Biopharmaceuticals made?
Who did Eiger collaborate with for Zokinvy® distribution in Japan?
What is the mission of Eiger Biopharmaceuticals?
Where can I find more information about Eiger Biopharmaceuticals?
What is the impact of Eiger's products in the field of biopharmaceuticals?
How can I contact Eiger Biopharmaceuticals for further inquiries?
